Table 4.
Major grade 3 or higher toxicity
| High dose (n=223) | Low dose (n=220)* | p value | |
|---|---|---|---|
| Haematological | |||
| Haemoglobin | 18(8) | 15(7) | 0·72 |
| Platelets | 13(6) | 11(5) | 0·83 |
| Neutrophils | 26(12) | 44(20) | 0·02 |
| Non-haematological | |||
| Deep-vein thrombosis or pulmonary embolism | 57(26) | 27(12) | 0·0003 |
| Infection or pneumonia | 35(16) | 20(9) | 0·04 |
| Hyperglycaemia | 25(11) | 14(6) | 0·09 |
| Cardiac ischaemia | 7(3) | 1 | 0·07 |
| Atrial fibrillation or flutter | 6(3) | 1 | 0·12 |
| Fatigue | 33(15) | 20(9) | 0·08 |
| Neuropathy | 5(2) | 4(2) | 0·1 |
| Non-neuropathic weakness | 25(11) | 9(4) | 0·01 |
| Summary | |||
| Any grade 3 or higher in first 4 months | 117(52) | 76(35) | 0·0001 |
| Any grade 3 or higher non-haematological toxicity at anytime during therapy |
146(65) | 106(48) | 0·0002 |
| Any grade 4 or higher non-haematological toxicity at anytime during therapy |
46(21) | 18(14) | 0·0002 |
| Early mortality (first 4 months) | 12(5) | 1 | 0·003 |
Data are number (%).
*
Data unavailable for two patients.